-
Nuggets overweight/obesity drug market GLP-1 receptor agonists do their part
Time of Update: 2022-01-02
At present, a variety of GLP-1 receptor agonists in China have been developed for overweight/obesity.
The drug is a long-acting molecule that is injected once a week and has been shown to effectively control blood sugar and reduce the weight of subjects in early clinical trials .
-
Many pharmaceutical companies took a fine in a few months!
Time of Update: 2022-01-02
For the production and sales of inferior drugs, a pharmaceutical company in Hunan Province was given a warning and a fine of 100,000 yuan; another pharmaceutical company was imposed a confiscation of illegal income of 2,211.
-
Tojo Pharmaceuticals Bevacizumab Approved for Listing
Time of Update: 2022-01-02
Article source: Medical Rubik's Cube InfoOn December 1, Toyo Pharmaceuticals announced that its self-developed bevacizumab injection TAB008 (trade name: Puxintin, intended to be used in English Pusintin) was approved by the National Medical Products Administration (NMPA) for the treatment of advanced, Metastatic or recurrent non-squamous non-small cell lung cancer and metastatic colorectal cancer .
-
The seventh batch of centralized procurement of medicines will be put on the agenda, and these varieties have met the conditions
Time of Update: 2022-01-02
After a three-day publicity period, on November 30, Shanghai Sunshine Pharmaceutical Purchasing Network issued the "Notice of the results of the selection", this also means that the sixth batch of national procurement (insulin special) officially "boots" .
-
Jiangsu draws a grand vision for the future development of the biopharmaceutical industry, sounding the clarion call for progress
Time of Update: 2022-01-02
It is reported that through R&D empowerment, the province's biomedical companies have achieved continuous innovation in multiple fields such as innovative drugs and medical devices .
-
In 2023, my country’s cardiovascular and cerebrovascular disease drug market will exceed 280 billion yuan
Time of Update: 2022-01-02
In the "Healthy China Action (2019-2030)", specific instructions were made on the prevention and treatment of cardiovascular and cerebrovascular diseases, and it was clearly necessary to promote the "three highs" co-management to carry out overweight and obesity, increased blood pressure and blood sugar, and dyslipidemia and other high-risk groups.
-
After 1 billion oral hypoglycemic drug Hausen, Sichuan pharmaceutical companies also entered the market
Time of Update: 2022-01-02
Figure 1: The status of companies reporting for the production of dapagliflozin tablets recentlySource: CDE official websiteDapagliflozin is a new oral hypoglycemic drug developed by Bristol-Myers Squibb (which has been transferred to AstraZeneca).
-
Centralized procurement and squeeze + medical anti-corruption upgrade, the living space of 3 million drug generation has become smaller and smaller
Time of Update: 2022-01-02
Some analysts pointed out that in the long run, the accelerated promotion of the centralized procurement policy will not only benefit the benign and high-quality development of the pharmaceutical industry, it will also play a certain role in anti-corruption of the pharmaceutical industry by cutting off bribery channels from the source .
-
Hengrui, Zhenbaodao, etc. have entered the market, and ADC drugs have entered the stage of competition
Time of Update: 2022-01-02
And cooperate with domestic and international R&D companies that focus on the research and development of ADC drug innovation products, such as Nuolin Biology and ImmunoGen, to strengthen and deepen the product innovation chain and the ADC field ecological chain .
-
November Pharmaceutical Events: "Marriage" continues, and pharmaceutical companies sign large orders
Time of Update: 2022-01-02
On November 11, Jichuan Pharmaceutical issued an announcement stating that the company reached an agreement with Tianjing Bio to obtain the development, production and commercialization of Tianjing Bio’s long-acting recombinant human growth hormone Itan growth hormone (TJ101) in mainland China Exclusive license, the total transaction amount does not exceed RMB 2.
-
With the prosperity of innovative drugs, new challenges will be presented in this field
Time of Update: 2022-01-02
In the context of the continuous expansion of demand for innovative drug R&D and commercial production, it is expected that new challenges will also be presented to the upstream pharmaceutical equipment field .
-
How will innovative drugs go in 2022?
Time of Update: 2022-01-02
At present, more and more local pharmaceutical companies are no longer confined to the domestic market, but are actively participating in global market competition in accordance with international standards by increasing R&D investment, and stepping out of the road to internationalization .
-
The number of chronic disease patients continues to grow, and the Internet chronic disease management market has huge potential
Time of Update: 2022-01-02
In fact, out of optimism about the market, pharmaceutical companies and Internet medical platforms are helping the prevention and treatment of chronic diseases by continuously developing chronic disease drugs and actively innovating service models .
-
Proprietary Chinese medicines are blooming everywhere!
Time of Update: 2022-01-02
The reason is that through price competition, the market can be reshuffled and those Chinese patent medicine companies with higher costs and average quality and curative effects can be eliminated .
-
How difficult is it for a new First-In-Class drug to be clinically approved by the FDA?
Time of Update: 2022-01-02
S. FDA A new drug listing application (NDA/BLA) has been approved; Hengrui Medicine’s Carrelizumab and Lugu Pharmaceutical’s Mannite Sodium Capsules are conducting international multi-center phase III clinical studies, including the United States .
-
Annual inventory: Interpreting the development of the pharmaceutical equipment industry in 2021 from 4 key words
Time of Update: 2022-01-02
A research report released during the year pointed out that after ten years of industrial chain development, domestic pharmaceutical equipment companies have gradually become a subdivision of China’s high-end manufacturing, domestic substitution has accelerated, export overseas business has grown rapidly, and the industry has gradually faded away from its cyclical nature.
-
221 drugs are included in Zhejiang "dual channel", including the four major domestic monoclonal antibodies
Time of Update: 2022-01-02
The industry predicts that as the "dual channel" policy is successively implemented in various places, it will help promote the reform of the drug management system in medical institutions, improve the service quality of medical insurance designated retail pharmacies, and solve the "difficulty in entering the hospital" and "difficulty in landing" negotiated drugs, so that medical insurance The negotiated drugs further achieved rapid increase in volume to better meet the people's drug demand .
-
NMPA publicly solicits opinions on "Guiding Principles of Pharmacovigilance Inspection (Draft for Comment)"
Time of Update: 2022-01-02
On December 1, the Comprehensive Department of the State Food and Drug Administration issued an announcement stating that, in order to implement the Pharmaceutical Administration Law of the People’s Republic of China and the Vaccine Administration Law of the People’s Republic of The Bureau organized the drafting of the "Guiding Principles for Pharmacovigilance Inspection (Draft for Soliciting Comments)" (see Annex 1), which is now open to the public for comments .
-
The pharmaceutical equipment market will continue to grow in the future. How can companies seize the opportunity?
Time of Update: 2022-01-02
In recent years, it can be seen that pharmaceutical machinery companies including Chutian and Tofflon have paid more attention to talent training, recruiting talents through various methods such as cooperation with schools and enterprises, and improving salaries; on the other hand, industry construction is also needed.
-
Stuximab introduced by BeiGene is approved to be marketed in China for the treatment of multicenter Casterman's disease
Time of Update: 2022-01-01
On December 2, the State Food and Drug Administration issued an announcement stating that it has recently passed the priority review and approval procedure to approve the import registration application of Stuximab (English name: Siltuximab for Injection) for the injection of rare disease drugs in urgent need of clinical use for human immunization.
